EFNB2 and cancer: Although nadolol has been relatively unexplored in its potential of treating certain cancers, a drug with a similar chemical makeup, propranolol, has been identified to treat multiple cancers including colon cancer, which is linked to the overexpression of the EphB2-ephrinB2 complex (Pantziarka et al., 2016; Işeri et al., 2014), and thus highlights significant repositioning opportunities for nadolol.